Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
62.3M
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
29.5M
-
Shares change
-
-4.31M
-
Total reported value, excl. options
-
$10.8M
-
Value change
-
-$793K
-
Put/Call ratio
-
0
-
Number of buys
-
35
-
Number of sells
-
-54
-
Price
-
$0.37
Significant Holders of Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) as of Q2 2025
97 filings reported holding ELEV - Elevation Oncology, Inc. - Common stock, par value $0.0001 per share as of Q2 2025.
Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.5M shares
of 62.3M outstanding shares and own 47.39% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (5.99M shares), BML Capital Management, LLC (5.89M shares), Aisling Capital Management LP (2.83M shares), VANGUARD GROUP INC (2.26M shares), Opaleye Management Inc. (1.44M shares), DELTEC ASSET MANAGEMENT LLC (1.44M shares), MILLENNIUM MANAGEMENT LLC (1.42M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (1.01M shares), Rangeley Capital, LLC (905K shares), and ExodusPoint Capital Management, LP (597K shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.